Cerebral Vasospasm Market Research Report- Forecast to 2032

Cerebral Vasospasm Market Research Report Information, By Diagnosis (Comoted Tomography Angiography, Digital Subtraction Angiography, Magnetic Resonance Angiography, and Transcranial Doppler), By Treatment (Nimodipine, Triple-H Therapy, Balloon Angioplasty, Vasopressors, Inotropes, Thrombolytic Agents, Anti-Inflammatory Agents), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Trauma Centers, Emergency Departments, and Others), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

ID: MRFR/MED/0909-HCR | 85 Pages | Author: Kinjoll Dey | March 2024         

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Cerebral Vasospasm Market, by Diagnosis

6.1 Introduction

6.2 CT scan

6.3 Computed Tomography Angiography (CTA)

6.4 Digital Subtraction Angiography (DSA)

6.5 Magnetic Resonance Angiography (MRA)

6.6 Transcranial Doppler (TCD)

Chapter 7. Global Cerebral Vasospasm Market, by Treatment

7.1 Introduction

7.2 Nimodipine

7.3 Triple-H therapy

7.4 Balloon Angioplasty

7.5 Vasopressors

7.6 Inotropes

7.7 Thrombolytic Agents

7.8 Anti-inflammatory Agents

Chapter 8. Global Cerebral Vasospasm Market, by End-Users

8.1 Introduction

8.2 Hospitals and Clinics

8.3 Ambulatory Surgical Centers

8.4 Trauma Centers

8.5 Emergency Departments

8.6 Others

Chapter 9. Global Cerebral Vasospasm Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Headsense Medical Ltd

11.1.1 Company Overview

11.1.2 Type Overview

11.1.3 Financials

11.2.4 Key Developments

11.1.5 SWOT Analysis

11.2 B. Braun Melsungen AG

11.2.1 Company Overview

11.2.2 Type Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Minnetronix, Inc

11.3.1 Company Overview

11.3.2 Type Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Bristol-Myers Squibb Company

11.4.1 Company Overview

11.4.2 Type/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Boehringer Ingelheim GmbH

11.5.1 Company Overview

11.5.2 Type Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 H. Lundbeck A/S

11.6.1 Company Overview

11.6.2 Type Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Koninklijke Philips N.V

11.7.1 Overview

11.7.2 Type Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 SIEMENS AG

11.8.1 Overview

11.8.2 Type Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Edge Therapeutics, Inc.

11.9.1 Overview

11.9.2 Type Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 GE Healthcare

11.10.1 Overview

11.10.2 Type Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Actelion Pharmaceuticals Ltd.

11.11.1 Overview

11.11.2 Type Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 Others

Chapter 12 Appendix

LIST OF TABLES

Table 1 Global Cerebral Vasospasm Market Industry Synopsis, 2023-2032

Table 2 Global Cerebral Vasospasm Market Estimates & Forecast, 2023-2032, (USD Million)

Table 3 Global Cerebral Vasospasm Market, by Region, 2023-2032, (USD Million)

Table 4 Global Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 5 Global Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 6 Global Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 7 North America: Prescribed Health Apps Market, by Diagnosis, 2023-2032, (USD Million)

Table 8 North America: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 9 North America: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 10 US: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 11 US: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 12 US: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 13 Canada: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 14 Canada: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 15 Canada: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 16 South America: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 17 South America: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 18 South America: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 19 Europe: Cerebral Vasospasm Market, Diagnosis, 2023-2032, (USD Million)

Table 20 Europe: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 21 Europe: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 22 Western Europe: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 23 Western Europe: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 24 Western Europe: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 25 Eastern Europe: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 26 Eastern Europe: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 27 Eastern Europe: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 28 Asia-Pacific: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 29 Asia-Pacific: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 30 Asia-Pacific: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

Table 31 Middle East & Africa: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)

Table 32 Middle East & Africa: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)

Table 33 Middle East & Africa: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Cerebral Vasospasm Market

Figure 3 Market Dynamics for the Global Cerebral Vasospasm Market

Figure 4 Global Cerebral Vasospasm Market Share, by Diagnosis 2020

Figure 6 Global Cerebral Vasospasm Market Share, by Treatment, 2020

Figure 6 Global Cerebral Vasospasm Market Share, by End-User, 2020

Figure 7 Global Cerebral Vasospasm Market Share, by Region, 2020

Figure 8 North America Cerebral Vasospasm Market Share, by Country, 2020

Figure 9 Europe Prescribed Health Apps Share, by Country, 2020

Figure 10 Asia-Pacific Cerebral Vasospasm Market Share, by Country, 2020

Figure 11 Middle East & Africa Cerebral Vasospasm Market Share, by Country, 2020

Figure 12 Global Cerebral Vasospasm Market: Company Share Analysis, 2020 (%)

Figure 13 Headsense Medical Ltd: Key Financials

Figure 14 Headsense Medical Ltd: Segmental Revenue

Figure 15 Headsense Medical Ltd: Geographical Revenue

Figure 16 B. Braun Melsungen AG: Key Financials

Figure 17 B. Braun Melsungen AG: Segmental Revenue

Figure 18 B. Braun Melsungen AG: Geographical Revenue

Figure 19 Minnetronix, Inc: Key Financials

Figure 20 Minnetronix, Inc: Segmental Revenue

Figure 21 Minnetronix, Inc: Geographical Revenue

Figure 22 Bristol-Myers Squibb Company: Key Financials

Figure 23 Bristol-Myers Squibb Company: Segmental Revenue

Figure 24 Bristol-Myers Squibb Company: Geographical Revenue

Figure 25 Boehringer Ingelheim GmbH: Key Financials

Figure 26 Boehringer Ingelheim GmbH: Segmental Revenue

Figure 27 Boehringer Ingelheim GmbH: Geographical Revenue

Figure 28 H. Lundbeck A/S: Key Financials

Figure 29 H. Lundbeck A/S: Segmental Revenue

Figure 30 H. Lundbeck A/S: Geographical Revenue

Figure 31 Koninklijke Philips N.V: Key Financials

Figure 32 Koninklijke Philips N.V: Segmental Revenue

Figure 33 Koninklijke Philips N.V: Geographical Revenue

Figure 34 SIEMENS AG: Key Financials

Figure 35 SIEMENS AG: Segmental Revenue

Figure 36 SIEMENS AG: Geographical Revenue

Figure 37 Edge Therapeutics, Inc.: Key Financials

Figure 38 Edge Therapeutics, Inc.: Segmental Revenue

Figure 39 Edge Therapeutics, Inc.: Geographical Revenue

Figure 40 GE Healthcare: Key Financials

Figure 41 GE Healthcare: Segmental Revenue

Figure 42 GE Healthcare: Geographical Revenue

Figure 43 Actelion Pharmaceuticals Ltd.: Key Financials

Figure 44 Actelion Pharmaceuticals Ltd.: Segmental Revenue

Figure 45 Actelion Pharmaceuticals Ltd.: Geographical Revenue

Cerebral Vasospasm Market Segmentation


Cerebral Vasospasm Diagnosis Outlook (USD Billion, 2018-2032)




  • Comoted tomography angiography




  • Digital subtraction Angiography




  • Magnetic Resonance Angiography




  • Transcranial Doppler




Cerebral Vasospasm Treatment Outlook (USD Billion, 2018-2032)




  • Nimodipine




  • Triple-H Therapy




  • Balloon Angioplasty




  • Vasopressors




  • Inotropes




  • Thrombolytic Agents




  • Anti-Inflammatory Agents




Cerebral Vasospasm End User Outlook (USD Billion, 2018-2032)




  • Hospitals




  • Clinics




  • Ambulatory surgical centers




  • Trauma Centers




  • Emergency Departments




  • Others




Cerebral Vasospasm Regional Outlook (USD Billion, 2018-2032)




  • North America Outlook (USD Billion, 2018-2032)




    • North America Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • North America Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors, Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • North America Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • US Outlook (USD Billion, 2018-2032)




    • US Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • US Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • US Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • CANADA Outlook (USD Billion, 2018-2032)




    • CANADA Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • CANADA Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • CANADA Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others








  • Europe Outlook (USD Billion, 2018-2032)




    • Europe Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Europe Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Europe Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Germany Outlook (USD Billion, 2018-2032)




    • Germany Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Germany Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Germany Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • France Outlook (USD Billion, 2018-2032)




    • France Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • France Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • France Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • UK Outlook (USD Billion, 2018-2032)




    • UK Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • UK Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • UK Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • ITALY Outlook (USD Billion, 2018-2032)




    • ITALY Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • ITALY Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • ITALY Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • SPAIN Outlook (USD Billion, 2018-2032)




    • Spain Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Spain Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Spain Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Rest Of Europe Outlook (USD Billion, 2018-2032)




    • Rest Of Europe Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • REST OF EUROPE Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • REST OF EUROPE Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others








  • Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Asia-Pacific Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Asia-Pacific Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Asia-Pacific Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • China Outlook (USD Billion, 2018-2032)




    • China Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • China Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • China Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Japan Outlook (USD Billion, 2018-2032)




    • Japan Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Japan Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Japan Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • India Outlook (USD Billion, 2018-2032)




    • India Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • India Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • India Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Australia Outlook (USD Billion, 2018-2032)




    • Australia Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Australia Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Australia Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)




    • Rest of Asia-Pacific Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Rest of Asia-Pacific Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Rest of Asia-Pacific Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others








  • Rest of the World Outlook (USD Billion, 2018-2032)




    • Rest of the World Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Rest of the World Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Rest of the World Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Middle East Outlook (USD Billion, 2018-2032)




    • Middle East Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Middle East Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Middle East Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Africa Outlook (USD Billion, 2018-2032)




    • Africa Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Africa Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Africa Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others






    • Latin America Outlook (USD Billion, 2018-2032)




    • Latin America Cerebral Vasospasm by Diagnosis




      • Comoted tomography angiography




      • Digital subtraction Angiography




      • Magnetic Resonance Angiography,




      • Transcranial Doppler






    • Latin America Cerebral Vasospasm by Treatment




      • Nimodipine




      • Triple-H Therapy




      • Balloon Angioplasty




      • Vasopressors,




      • Inotropes,




      • Thrombolytic Agents,




      • Anti-Inflammatory Agents






    • Latin America Cerebral Vasospasm by End User




      • Hospitals




      • Clinics




      • Ambulatory surgical centers,




      • Trauma Centers,




      • Emergency Departments,




      • Others







Leading companies partner with us for data-driven Insights.
Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon Report List icon

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid